Reviewer's report

Title: Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)

Version: 2 Date: 26 April 2015

Reviewer: Flavia Ballocca

Reviewer's report:

This is an interesting manuscript involving the pressing topic of economic impact of new therapies. It considers both short and long term costs of the use of fondaparinux in patients with acute coronary syndromes. Considering the complex subject, mainly focused on economic features more than on medical ones, it is quite difficult to make a proper revision for a physician. The basis seem to be well posed, and the analysis is complete. The two limits I see are:
- to use US patients derived from OASIS-5 trial, but to use a life-time model in a Canadian hospital setting for cost-effectiveness analysis, while these populations may not be comparable.
- when considering bleedings, to assume that they are not affecting long-term prognosis, while a major bleeding may affect it.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interest.